Summary
In the present study, the actions of several compounds with different intrinsic activities and BDZ receptor selectivity were examined in two well established animal models of anxiety: the open field test (OFT) and Vogel's punished drinking text (VT). Full agonists at the BDZ-GABA a receptor (midazolam and diazepam) showed anxiolytic-like effects in both tests; however, the doses necessary to disinhibit animal behavior controlled by fear were higher in the VT than in the OFT. None of the partial BDZ receptor agonists studied (bretazenil, Ro 19–8022 and abecarnil) diminished neophobia-like behavior of rats in the OFT, and their sedative influence on gross behavior prevailed. On the other hand, all three drugs produced a clear-cut anxiolytic effect in the VT. A selective BDZ1 receptor subtype full agonist (zolpidem) had a similar profile of action to that of partial agonists with an even stronger sedative effect in the OFT. Alpidem (a selective BDZ1 receptor partial agonist) did not reveal any anxiolytic action in either test. Flumazenil (an antagonist at the BDZ-GABA a receptors) also produced no effect in the OFT, or the VT. An inverse BDZ receptor agonist, β-carboline-3-carboxylate methyl ester (β-CCM), evoked an anxiogenic-like response in the OFT, but not in the VT. In summary, it appeared that partial agonists and selective ligands at BDZ1 receptors revealed less advantageous anxiolytic-like action than did full allosteric GAB A a receptor modulators. This study also indicates the test dependent profiles of action of BDZ-GABA a receptor ligands. It also indirectly suggests a different neurobiological background underlying the applied tests.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Auta J, Giusti P, Guidotti A, Costa E (1994) Imidazenil, a partial positive allosteric modulator of GABA-A receptors exhibits low tolerance and dependence liabilities in the rat. J Pharmacol Exp Ther 270: 1262–1269
Benavides J, Peny B, Ruano D, Vitorica J, Scatton B (1993) Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res 604: 240–250
Chen S-W, Chem HA, Davies F, Loew GH (1996) Putative benzodiazepine partial agonists demonstrate receptor heterogeneity. Pharmacol Biochem Behav 53: 87–97
Davies MF, Onaivi ES, Chen SW, Maguire PA, Tsai NF, Loew GH (1994) Evidence for central benzodiazepine heterogeneity from behavioral tests. Pharmacol Biochem Behav 49: 47–56
Duncan GE, Breese GR, Criswell HE, McCown TJ, Herbert JS, Devaud LL, Morrow AL (1995) Distribution of3pH] zolpidem binding sites in relation to messenger RNA encoding the α1 β2 and γ2 subunits of GABAA receptors in rat brain. Neurosci 4: 1113–1128
Griebel G, Sanger JD, Perrault G (1996) The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands. Psychopharmacol 124: 245–254
Hogg S, File SE (1994) Regional differences in rat benzodiazepine binding in response to novelity and cat odour. Neuropharmacol 33: 865–868
Jenck F, Moreau J-L, Bonetti EP, Martin JR, Haefely WE (1992) Ro 19-8022 a nonbenzodiazepine partial agonist at benzodiazepine receptors: neuropharmacological profile of a potent anxiolytic. J Pharmacol Exp Ther 262: 1121–1127
Jessa M, Nazar M, Bidzinski A, Pdaźnik A (1996) The effect of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. Eur Neuropsychopharmacol 6: 55–61
Jones GH, Schneider C, Schneider HH, Seidler J, Cole BJ, Stephens DN (1994) Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies. Psychopharmacol 114: 191–199
Knoflach F, Drescher U, Scheurer I, Mahlerber P, Möhler H (1993) Full and partial agonism displayed by benzodiazepine receptor ligands at different recombinant GABA-A receptor subtypes. J Pharmacol Exp Ther 266: 385–391
Luddens H, Korpi ER (1995) Biological function of GABA-A/benzodiazepine receptor heterogeneity. J Psychiatr Res 29: 77–94
Martin JR, Pieri L, Bonetti EP, Schaffner R, Burkard WP, Cumin R, Haefely WE (1988) Ro 16-6028: a novel anxiolytic acting as a partial agonist at a benzodiazepine receptor. Pharmacopsychiatry 21: 381–385
Martin JR, Schöch P, Jenck F, Moreau J-L, Haefely WE (1993) Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero. Psychopharmacol 111: 415–422
Möhler H, Malherbe P, Draguhn A, Sigel E, Sequier JM, Persohn E, Richards JG (1990) In: Biggio G, Costa E (eds) GABA-A receptor subunits: functional expression and gene localization of GABA and benzodiazepine receptor subtypes. Raven Press, New York, pp 23–34
Ozawa M, Nakad Y, Sugimachi K, Yabuuchi F, Akai T, Mizuta E, Kuno S, Yamaguchi M (1994) Pharmacological characterization of the novel anxiolytic beta-carboline abecarnil in rodents and primates. Jpn J Pharmacol 64: 179–187
Płaźnik A (1995) Pharmacology of tolerance to benzodiazepine ligands. Pol J Pharmacol 47: 489–499
Płaźnik A, Pałejko W, Nazar M, Jessa M (1994) Effects of antagonists at NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 4: 503–512
Pollard GT, Howard JL (1990) Effect of drugs on punished behavior: pre-clinical test for anxiolytics. Pharmacol Ther 45: 403–424
Potokar J, Nutt DJ (1994) Anxiolytic potential of benzodiazepine receptor partial agonists. CNS Drugs 1: 305–315
Pribilla I, Neuhaus R, Hillmann M, Turner J, Stephens DN, Schneider HH (1993) Abecarnil is full agonist at some, and a partial agonist at other recombinant GABA A receptor subtypes. In: Stephens DN (ed) Anxiolytic B carbolines: from molecular biology to the clinic. Springer, Berlin Heidelberg New York Tokyo, pp 50–61 (Psychopharmacology series, vol 11)
Serra M, Ghiani CA, Motzo C, Porceddu ML, Biggio G (1994) Long-term treatment with abecarnil fails to induce tolerance in mouse. Eur J Pharmacol 259: 1–6
Stefański R, Pałejko W, Kostowski W, Płaźnik A (1992) The comparison of benzodiazepines derivatives and serotonergic agonists in two animal models of anxiety. Neuropharmacol 31: 1251–1258
Stephens DN, Schneider HH, Kehr W, Andrews JS, Retting KJ, Turski L, Schmiechen R, Turner JD, Jensen LH, Petersen EN (1990) Abecarnil, a metabolicaly stable, anxioselective beta-carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther 253: 334–343
Vorobjev VS, Sharonova IN, Skrebitsky VG, Schneider HH, Stephens DN (1995) Abecarnil enhances GABA-induced currents in acutely isolated cerebellar Purkinje cells. Neuropharmacol 34: 157–163
Zivkovic B, Morel E, Joly D, Perrault GH, Sanger DJ, Lloyd KG (1990) Pharmacological and behavioral profile of alpidem as an anxiolytic. Pharmacopsychiatry 23 [Suppl]: 108–113
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nazar, M., Jessa, M. & Płaźnik, A. Benzodiazepine-GABAA receptor complex ligands in two models of anxiety. J. Neural Transmission 104, 733–746 (1997). https://doi.org/10.1007/BF01291890
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01291890